Observational studyBMC pregnancy and childbirth2026
Maternal serum pepsinogen-1 levels in severe hyperemesis gravidarum and the need for hospitalization: a prospective study.
Observational study in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06581796 (Examination of the Maternal Serum Pepsinogen-1 in Patients Diagnosed With Severe Hyperemesis Gravidarum), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Examination of the Maternal Serum Pepsinogen-1 in Patients Diagnosed With Severe Hyperemesis Gravidarum: A Prospective Case-control Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to examine whether there is a statistical difference in maternal serum pepsinogen-1 (MSPG-1) between pregnant women with severe hyperemesis gravidarum (HG) and those with moderate HG managed without hospitalization and to explore an MSPG-1 threshold associated with hospitalization in pregnant women with HG. MATERIAL
methodsThis prospective observational study was conducted in a tertiary referral hospital between August 31, 2024, and November 21, 2024. Singleton pregnancies hospitalized with severe nausea and vomiting in the first trimester and ketonuria in the urine spot test were considered severe HG. The control group comprised symptomatic pregnant women diagnosed with moderate HG who did not require hospitalization. The suitability of the MSPG-1 for hospitalization was determined by analyzing the Receiver Operating Characteristics Curve.
resultsMSPG-1 levels were significantly lower in pregnant women with severe HG than in pregnant women with moderate HG. The optimal MSPG-1 cut-off associated with hospitalization was ≤ 67.7 ng/mL (84% sensitivity and 66% specificity) for severe HG.
conclusionLower MSPG-1 levels were associated with more severe clinical presentation and hospitalization in HG patients. The optimal value for MSPG-1 (≤ 67.7 ng/mL) with a specificity of 66% and a sensitivity of 84% may serve as a potential cut-off value to support hospitalization decisions in patients with hyperemesis gravidarum. However, it should be noted that the design of the study, in which only one center is involved, requires external validation.
trial registrationThe study is registered at www.clinicaltrails.gov [registration number: NCT06581796; registration date: 30/August/2024].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.